-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WJdoRw4ywEVZ01ZbiIei7nk53P5gcde9Py8HPCkcDFSRXhILTyvN4lRhp8Nkhwvl
 lQVx5cbtmGwGlBYQyfHZ8g==

<SEC-DOCUMENT>0000927946-04-000089.txt : 20040318
<SEC-HEADER>0000927946-04-000089.hdr.sgml : 20040318
<ACCEPTANCE-DATETIME>20040318105434
ACCESSION NUMBER:		0000927946-04-000089
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040316
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20040318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		04676909

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8kmar.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC. 8K
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K (dated 10/31/2003</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>March 16, 2004</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u>Indiana</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
0-23357</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
35-1345024</u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
2701 Kent Avenue<br>
<u>West Lafayette, Indiana</u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u>47906-1382</u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
(765) 463-4527</u></font></TD></TR>
<TR VALIGN=top><TD> </TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>



<PAGE>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
The information in this Form 8-K is being furnished and shall not be deemed
&#147;filed&#148; for the purpose of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section.
The information in this Form 8-K shall not be incorporated by reference into any
registration statement or other document pursuant to the Securities Act of 1933,
as amended.</FONT></P>

<!-- MARKER FORMAT-SHEET="Indented Head Left" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Not applicable.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Not applicable.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
99.1&nbsp;&nbsp;&nbsp;&nbsp;Bioanalytical Systems, Inc. press release, issued
March 16, 2004.</font></P>


<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
On March 16, 2004, Bioanalytical Systems, Inc. (the "Company") issued a press
release announcing that the Company has named Michael R. Cox as Vice
President-Finance, Treasurer and Chief Financial Officer effective April 1,
2004.</font></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
The full text of the press release is furnished as exhibit 99.1 to this Form
8-K.</FONT></P>



<BR>
<BR>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=1>
- - 2 -</font></P>

<PAGE>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SIGNATURES </FONT></H1>
<BR>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;March 17, 2004</FONT></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc.<BR>
<BR>
<BR>
<BR>

By:&nbsp;&nbsp;/s/&nbsp;&nbsp;Michael P. Silvon<HR>
Michael P. Silvon<BR>
Chief Financial Officer<BR>
</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U><b>Exhibit Index</b></U> </FONT></H1>
<BR>


<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD valign=bottom WIDTH=20%><div align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<u>Exhibit No.</U></FONT></div></TD>

<TD valign=bottom WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<u>Description</U></FONT></TD>
</TR>
</TABLE>
<BR>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><div align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
99.1</FONT></div></TD>

<TD valign=bottom WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc. press release, issued March 16, 2004.</FONT></TD>
</TR>
</TABLE>

</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1 - PRESS RELEASE DATED MARCH 16, 2004
<TEXT>








<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit 99.1</U> </FONT></H1>
<BR>

<!-- MARKER FORMAT-SHEET="Head Right" FSL="Default" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
<B>FOR MORE INFORMATION:</B><BR>
Alice Schwind<BR>
765.497.8458 <BR>
alice@bioanalytical.com<BR>
&#151; OR&#151;<BR>
Evan Smith, CFA / Erica Pettit<BR>
KCSA Worldwide<BR>
212.896.1251/212.896.1248<BR>
esmith@kcsa.com/epettit@kcsa.com </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc. Appoints New Chief Financial Officer<BR>
<BR>
Financial and Life Sciences Background Strengthens Management Team </FONT></H1>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
WEST LAFAYETTE, IN, March 16, 2004 &#150; Bioanalytical Systems, Inc. (BASi)
(Nasdaq:BASI) has named Michael R. Cox as Vice President-Finance, Treasurer and
Chief Financial Officer effective April 1, 2004.</FONT></P>

<!-- MARKER FORMAT-SHEET="Exhibit Header" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Mr. Cox has over 20 years of senior financial and operating management
experience. Prior to joining BASi he was Treasurer and CFO of Integrity
Pharmaceutical, an Indiana-based specialty pharmaceutical company focused on
women&#146;s health. He also served as Senior VP, CFO and COO at Intergen
Company, a developer of therapeutic, diagnostic and research products for
biotech. Earlier, Mr. Cox founded two environmental services companies. As CEO
he led both through IPO&#146;s and NASDAQ listing. He began his career as a CPA
with Touche Ross &amp; Co. where he was elected to Partner and Director of Audit
Operations in southeastern Connecticut. Mr. Cox has a BA in business from the
University of North Carolina.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Peter T. Kissinger, Chairman and CEO, commented, &#147;Mike has a strong
business background and understands what is needed to take BASi to a higher
level. The breadth and depth of his financial and life science experiences will
be key to maintaining momentum in our growth initiative and to improving our
efficiency. I look forward to working with him and learning from
him.&#148;</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
As part of his compensation package, the Company agreed to grant Mr. Cox
incentive options to purchase 25,000 common shares under its 1997 Employee
Incentive Stock Option Plan and non-qualified options to purchase an additional
25,000 of its common shares outside the Option Plan, all at the per-share market
price at the close of business on the last trading day prior to the date Mr. Cox
commences employment with the Company. The option grants are contingent upon Mr.
Cox commencing employment with the Company.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Michael P. Silvon, currently interim CFO, will resume his role as Vice
President-Corporate Planning and Development.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
BASi is a pharmaceutical development company that provides contract research
services and trace chemical analysis instruments to the world&#146;s leading
drug development and medical device companies. The company focuses on developing
innovative services and products that increase efficiency and reduce the cost of
taking new drugs to market. Visit <U>www.bioanalytical.com</U> for more
information about BASi.</FONT></P>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<I>This release contains forward-looking statements that are subject to risks
and uncertainties including, but not</I><BR>
<I>limited to, risks and uncertainties related to the development of products
and services, changes in technology,</I><BR>
<I>industry standards and regulatory standards, and various market and operating
risks detailed in the company&#146;s</I><BR>
<I>filings with the Securities and Exchange Commission.</I></font></P>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
# # # # #</font></P>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
